ARVN Stock Overview
A clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Arvinas, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.13 |
| 52 Week High | US$53.08 |
| 52 Week Low | US$13.57 |
| Beta | 1.98 |
| 11 Month Change | -13.34% |
| 3 Month Change | -28.67% |
| 1 Year Change | -4.16% |
| 33 Year Change | -70.33% |
| 5 Year Change | 3.89% |
| Change since IPO | 56.57% |
Recent News & Updates
Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aug 02
Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive
Jul 12Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation
Jun 27Recent updates
Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aug 02Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive
Jul 12Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation
Jun 27Arvinas: Behind The Huge Rally
Mar 03What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You
Feb 25News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts
Aug 13There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price
May 05Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)
Feb 24Arvinas initiated Overweight at Barclays on attractive therapeutic platform
Sep 09Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment
Aug 19Arvinas: Still Holding, Just Not Buying More
May 23Shareholder Returns
| ARVN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 5.5% | 1.8% | 3.1% |
| 1Y | -4.2% | 17.9% | 24.9% |
Return vs Industry: ARVN underperformed the US Pharmaceuticals industry which returned 17.4% over the past year.
Return vs Market: ARVN underperformed the US Market which returned 25.4% over the past year.
Price Volatility
| ARVN volatility | |
|---|---|
| ARVN Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ARVN's share price has been volatile over the past 3 months.
Volatility Over Time: ARVN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 445 | John Houston | www.arvinas.com |
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial.
Arvinas, Inc. Fundamentals Summary
| ARVN fundamental statistics | |
|---|---|
| Market cap | US$1.72b |
| Earnings (TTM) | -US$323.40m |
| Revenue (TTM) | US$93.30m |
18.5x
P/S Ratio-5.3x
P/E RatioIs ARVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARVN income statement (TTM) | |
|---|---|
| Revenue | US$93.30m |
| Cost of Revenue | US$0 |
| Gross Profit | US$93.30m |
| Other Expenses | US$416.70m |
| Earnings | -US$323.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.71 |
| Gross Margin | 100.00% |
| Net Profit Margin | -346.62% |
| Debt/Equity Ratio | 0.1% |
How did ARVN perform over the long term?
See historical performance and comparison